We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Triple Therapy with Rosiglitazone (RSG) or Insulin (INS) and Associated Medical Resource Use (MRU) and Costs in Type 2 Diabetes (T2D).
- Authors
Palmer, Liisa; Baser, Onur; Arondekar, Bhakti; Horblyuk, Ruslan
- Abstract
Clinical trials have demonstrated that intensive therapy to control blood glucose levels results in lower rates of complications and can substantially reduce the economic burden of T2D. Historically, T2D therapy has been based on a stepwise approach. When patients fail to achieve a therapeutic goal of controlling blood glucose, RSG or INS are often used as add-on agents to a commonly used combination therapy with metformin (Met) and sulfonylurea (SU). The purpose of this study was to evaluate the MRU and costs associated with triple therapy with RSG (Met+SU+RSG) (n=2,821) relative to those associated with triple therapy with INS (Met+SU+INS) (n=591). MRU and costs for patients with at least 6 months of Met+SU dual therapy prior to the addition of RSG or INS were evaluated for the 18-month period following initiation of the triple therapy using a large managed care claims database for the period of January 1,2000 - March 31, 2005. After controlling for baseline differences (age, gender, comorbidities), Met+SU+RSG had significantly fewer hospitalizations (p<0.05) and physician office visits (p<0.05) than Met+SU+INS. Prescription costs for Met+SU+RSG ($5,232) were significantly higher than for Met+SU+INS ($4,758, p=0.005), while costs of medical services - driven by fewer hospitalizations - were significantly lower for Met+SU+RSG ($8,982) compared to Met+SU+INS ($12,030, p<0.0001). Overall costs of Met+SU+RSG ($12,991) were significantly lower than those of Met+SU+INS ($14,581, p<0.0001). This analysis indicates that over 18 months lower medical services costs associated with RSG triple therapy have potential to offset higher pharmacy costs resulting ha significant overall cost savings as compared to triple therapy with INS.
- Subjects
HYPOGLYCEMIC agents; INSULIN therapy; TYPE 2 diabetes; BLOOD sugar; HYPOGLYCEMIC sulfonylureas; MEDICAL care costs
- Publication
Diabetes, 2007, Vol 56, pA650
- ISSN
0012-1797
- Publication type
Article